ABMED · GLOBAL REGULATORY & MARKET ACCESS
American markets
38 international markets (countries and regional markets) in our service materials; each jurisdiction has its own requirements.
Find your target market
INVIMA
Colombia
Market access overview
Assess INVIMA risk classification, product grouping and the applicable registration route. Define the registration holder and qualified importer roles separately.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
DIGEMID
Peru
Market access overview
Assess DIGEMID sanitary registration by device risk and product characteristics. Confirm local responsibility, Spanish documents and the applicable free-sale and authentication requirements.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
ANVISA
Brazil
Market access overview
ANVISA general devices use classes I–IV. Classes I/II generally follow notification and III/IV registration; assess the applicable BGMP/CBPF evidence and local holder separately.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
ANMAT
Argentina
Market access overview
Assess the current ANMAT risk-based registration and any eligible simplified route. Confirm the qualified local applicant/importer and Spanish-language evidence.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
ISP / ANDIM
Chile
Market access overview
Check the ISP/ANDIM controlled-product scope and implementation stage before deciding whether sanitary registration applies. Registration, import clearance and use/distribution procedures are distinct.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
ARCSA
Ecuador
Market access overview
Use the applicable ARCSA medical-device framework. Confirm risk class, ordinary or eligible simplified registration, the authorised local applicant and Spanish information.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
Health Canada
Canada
Market access overview
Class I generally does not require an MDL, while establishment MDEL obligations must still be assessed. Classes II–IV require the applicable MDL and MDSAP quality evidence.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
COFEPRIS
Mexico
Market access overview
Assess COFEPRIS classification and the currently available ordinary or reliance route for the specific product. Foreign approvals or free-sale certificates do not automatically establish Mexican acceptance.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
FDA
United States
Market access overview
FDA device classification and product code determine whether exemption, 510(k), De Novo or PMA applies. Establishment registration and listing do not constitute FDA approval.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
Ministry of Health
Costa Rica
Market access overview
Assess the EMB category and risk class under Costa Rica’s applicable framework, local applicant responsibility, Spanish evidence and the registration/import arrangements.
Confirm product classification and grouping, qualified local responsibility, technical and quality evidence, labelling, and the applicable application and post-market steps.
Based on the regulatory section of ABMED’s 38-market report, with source material dated 17 November 2026. Confirm current rules and the specific product before implementation. Market coverage does not imply a company office in every market.